摘要
目的观察依折麦布对危险评估为高危的高脂血症并肝损患者的疗效和安全性。方法肝损的高胆固醇血症30例和混合型高脂血症35例予依折麦布治疗,观察治疗后血脂变化、肝毒性和肌毒性。结果治疗后第4、8周的肝功能和CK均未升高。两组治疗8周后血LDL-C下降明显,混合型高脂血症组血TC和TG治疗8周后均有下降,差异具有统计学意义(P<0.05)。结论他汀类药物的肝毒性和肌毒性等使高脂血症并肝损的患者无法或惧怕使用他汀药物。依折麦布几乎不经细胞色素P450酶代谢,依折麦布单药治疗8周也能使合并肝损的高危高脂血症患者的血LDL-C和TC进一步下降,有良好的安全性,有理由相信血脂下降能使高危患者最终获益。
Objective To observe of ezetimibe on the risk assessment for the risk of liver damage in patients with hyperlipidemia and the efficacy and safety. Methods Liver damage in 30 patients with hypercholesterolemia and mixed hyperlipidemia ezetimibe 35 patients treated for blood lipid changes and liver toxicity and muscle toxicity. Results After 4,8 weeks of treatment, liver function and CK were not increased, two groups after 8 weeks of treatment serum LDL-C significantly decreased, mixed hyperlipidemia group of blood TC and TG were decreased after 8 weeks treatment （ P 〈 0.05 ）. Conclusion Statin drugs such as liver toxicity and muscle toxicity and liver damage that hyperlipidemia in patients unable or afraid to use statin drugs.Almost without a break by Mab enzyme cytoehrome P450 metabolism, ezetimibe monotberapy for 8 weeks also enable the combined risk of liver damage in the blood of patients with hyperlipidemia TC and LDL-C further decline, with good security reason to believe that decreased blood lipid can ultimately benefit patients at high risk.
出处
《中国现代医生》
2011年第21期76-77,79,共3页
China Modern Doctor
关键词
依折麦布
肝损
高脂血症
Ezetimibe
Liver damage
Hyperlipidemia
